NDA 17-037/S-158
Page 24
activated Factor X and inhibiting the conversion of prothrombin to thrombin.
Once active thrombosis
has developed, larger amounts of heparin can inhibit further coagulation by inactivating thrombin and
preventing the conversion of fibrinogen to fibrin. Heparin also prevents the formation of a stable fibrin
clot by inhibiting the activation of the fibrin stabilizing factor.
Bleeding time is usually unaffected by heparin. Clotting time is prolonged by full
therapeutic doses of
heparin; in most cases, it is not measurably affected by low doses of heparin. Loglinear plots of
heparin plasma concentrations with time, for
a wide range of dose levels, are linear, which suggests the
absence of zero order processes. Liver and the reticulo-endothelial
system are the sites of
biotransformation. The biphasic elimination curve, a rapidly declining alpha phase (t
1/2
= 10 min), and
after the age of 40 a slower beta phase, indicates uptake in organs. The
absence of a relationship
between anticoagulant half-life and concentration half-life may reflect factors such as protein binding
of heparin.
Patients over 60 years of age, following similar doses of heparin, may have higher plasma
levels of
heparin and longer activated partial thromboplastin times (APTTs) compared with patients under 60
years of age.
Heparin does not have fibrinolytic activity; therefore, it will not lyse existing clots.
INDICATIONS AND USAGE
HEP-LOCK U/P (Preservative-Free Heparin Lock Flush Solution, USP) is intended
to maintain
patency of an indwelling venipuncture device designed for intermittent injection or infusion therapy or
blood sampling. Heparin Lock Flush Solution may be used following initial placement of the device in
the vein, after each injection of a medication or after withdrawal of blood for laboratory tests. (See
Dostları ilə paylaş: